Visual Outcomes in the Management of Diabetic Maculopathy in Central Australia

References

• Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339–349. doi:10.1016/S2214-109X(13)70113-X.
   PubMed Web of Science ®Google Scholar
• Regnier SA, Malcolm WA. Efficacy comparison of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. Value Health. 2015;18(7):A416. doi:10.1016/j.jval.2015.09.1009.
   Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Michels S, et al. The role of anti-VEGF therapy in the treatment of diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2016;47(6 Suppl):S4–S14. doi:10.3928/23258160-20160601-02.
   Web of Science ®Google Scholar
• Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep. 2014;14(8):510. doi:10.1007/s11892-014-0510-4.
   PubMed Web of Science ®Google Scholar
• ETDRS. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology. 1991;98(5 Suppl):766–785.
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–136. doi:10.1016/S0140-6736(09)62124-3.
   PubMed Web of Science ®Google Scholar
• Keel S, Foreman J, Xie J, van Wijngaarden P, Taylor HR, Dirani M. The prevalence of self-reported diabetes in the Australian national eye health survey. PLoS One. 2017;12(1):e0169211. doi:10.1371/journal.pone.0169211.
   PubMed Web of Science ®Google Scholar
• Keel S, Xie J, Foreman J, van Wijngaarden P, Taylor HR, Dirani M. The prevalence of diabetic retinopathy in Australian adults with self-reported diabetes: the national eye health survey. Ophthalmology. 2017;124(7):977–984. doi:10.1016/j.ophtha.2017.02.004.
   PubMed Web of Science ®Google Scholar
• ETDRS. Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103(12):1796–1806. doi:10.1001/archopht.1985.01050120030015.
   PubMedGoogle Scholar
• Fong DS, Strauber SF, Aiello LP, et al. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema: writing committee for the diabetic retinopathy clinical research, network. Arch Ophthalmol. 2007;125(4):469–480.
   PubMedGoogle Scholar
• Kaufman SC, Ferris FL 3rd, Seigel DG, Davis MD, DeMets DL. Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic retinopathy study report #13. Invest Ophthalmol Vis Sci. 1989;30:23–28.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The wisconsin epidemiologic study of diabetic retinopathy. VI. Retinal photocoagulation. Ophthalmology. 1987;94(7):747–753. doi:10.1016/S0161-6420(87)33525-0.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Hillenkamp J, Sivaprasad S, et al. Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clin Ophthalmol. 2016;10:1103–1110. doi:10.2147/OPTH.S100764.
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal Bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–979. doi:10.1001/archophthalmol.2012.393.
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal Bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–1086 e1072. doi:10.1016/j.ophtha.2010.03.045.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results: diabetic retinopathy clinical research network. Ophthalmology. 2012;119(11):2312–2318. doi:10.1016/j.ophtha.2012.08.022.
   PubMed Web of Science ®Google Scholar
• Hang P. Treatment of focal vs diffuse diabetic macular edema: combination laser and anti-VEGF therapy could be the new gold standard. Retinal Physician. 2017;19.
   Google Scholar
• Distefano LN, Garcia-Arumi J, Martinez-Castillo V, Boixadera A. Combination of anti-VEGF and laser photocoagulation for diabetic macular edema: a review. J Ophthalmol. 2017;2017:2407037.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96(5):688–693. doi:10.1136/bjophthalmol-2011-300726.
   PubMed Web of Science ®Google Scholar
• Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888–896. doi:10.1001/jamaophthalmol.2016.1669.
   PubMed Web of Science ®Google Scholar
• Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology. 2011;118(9):1827–1833. doi:10.1016/j.ophtha.2010.12.034.
   PubMed Web of Science ®Google Scholar
• Thomas M, Weekes AJ, Thomas MC. The management of diabetes in indigenous Australians from primary care. BMC Public Health. 2007;7:303. doi:10.1186/1471-2458-7-303.
   PubMed Web of Science ®Google Scholar